Efficacy, safety and quality of life (QoL) with Lanreotide Autogel (LAN) 120 mg every 14 days in progressive pancreatic or midgut neuroendocrine tumors (NETs): CLARINET FORTE study results
Pavel ME, Cwikla JB, Lombard-Bohas C, Borbath , Shah T, Pape UF, Thanh TXM, Houchard A, Ruszniewski P (2021)
Publication Type: Conference contribution
Publication year: 2021
Journal
Publisher: WILEY
City/Town: HOBOKEN
Pages Range: 143-143
Conference Proceedings Title: JOURNAL OF NEUROENDOCRINOLOGY
Authors with CRIS profile
Involved external institutions
Hôpital Edouard Herriot
France (FR)
University of Warmia and Mazury in Olsztyn
Poland (PL)
University of Paris 4 - Paris-Sorbonne / Université paris IV Paris-Sorbonne
France (FR)
Queen Elizabeth Hospital Birmingham
United Kingdom (GB)
Ipsen Pharma
France (FR)
Charité - Universitätsmedizin Berlin
Germany (DE)
Cliniques universitaires Saint-Luc (CHU St-Luc)
Belgium (BE)
France (FR)
University of Warmia and Mazury in Olsztyn
Poland (PL)
University of Paris 4 - Paris-Sorbonne / Université paris IV Paris-Sorbonne
France (FR)
Queen Elizabeth Hospital Birmingham
United Kingdom (GB)
Ipsen Pharma
France (FR)
Charité - Universitätsmedizin Berlin
Germany (DE)
Cliniques universitaires Saint-Luc (CHU St-Luc)
Belgium (BE)
How to cite
APA:
Pavel, M.E., Cwikla, J.B., Lombard-Bohas, C., Borbath, ., Shah, T., Pape, U.F.,... Ruszniewski, P. (2021). Efficacy, safety and quality of life (QoL) with Lanreotide Autogel (LAN) 120 mg every 14 days in progressive pancreatic or midgut neuroendocrine tumors (NETs): CLARINET FORTE study results. In JOURNAL OF NEUROENDOCRINOLOGY (pp. 143-143). HOBOKEN: WILEY.
MLA:
Pavel, Marianne Ellen, et al. "Efficacy, safety and quality of life (QoL) with Lanreotide Autogel (LAN) 120 mg every 14 days in progressive pancreatic or midgut neuroendocrine tumors (NETs): CLARINET FORTE study results." Proceedings of the 18th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease HOBOKEN: WILEY, 2021. 143-143.
BibTeX: Download